Alpha Tau (NASDAQ: $DRTS) Announces Third Quarter 2026 Financial Results and Provides Corporate Update
“provides runway for continued clinical advancement and commercial preparation”
https://t.co/g5s8oQSARV
“Is Alpha Tau (NASDAQ: $DRTS) on the way to FDA approval for the treatment of Brain Cancer? Encouraging results are in”
Israeli media coverage is warming up ahead of the investor call, with trading on the TASE halted
$DRTS Trading has been halted on the TASE!
Alpha Tau shared mind blowing interim results from their REGAIN trial for Recurrent GBM, with an Investor Call coming today on November 16, 2026, at 8:30 am ET.
Alpha Tau (NASDAQ: $DRTS) Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events
The call will feature REGAIN principal investigator Dr. @joshuapalmermd of The Ohio State University; Uzi Sofer, CEO of Alpha Tau; Robert Den, MD, Chief Medical Officer of Alpha Tau; and Raphi Levy, CFO of Alpha Tau.
Can’t wait to see the abstract authored by REGAIN study principal investigator Dr. @joshuapalmermd, marking the trial’s first appearance at a scientific meeting, including new Recurrent GBM trial data.
The countdown is over! The world's neuro-oncology community is coming together in Philadelphia for the 31st Annual Meeting and Education Day. We're excited to welcome researchers, clinicians, trainees, advocates, and partners from around the globe. Share/follow along > #SNO2026.
$DRTS Price Target Raised to $22 by Piper Sandler
The firm upgrades Alpha Tau to Overweight (the strongest buy rating) ahead of the new rGBM trial data coming out this week!
A Demonstration Of The $DRTS Treatment For Brain Cancer
A significant update from the REGAIN trial for Recurrent GBM is coming within days!
Alpha Tau CEO said to follow closely
The Alpha DaRT treatment uses the existing biopsy hole to insert the alpha radiation sources directly into the tumor, destroying it from the inside while sparing the healthy tissue around it, all in a single session within minutes
Early results have shown 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile
The $DRTS accumulation continues, as the index funds keep loading up just days before the next trail update
As Alpha Tau is set to share new data from the REGAIN trial for Recurrent GBM, it’s trading on the TASE at ~$14.5
As the TA-90 and TA-125 index inclusions come near, $DRTS volume on the TASE is up to millions in ILS, trading at the equivalent of ~$13.5
Alpha Tau will be sharing new data from the REGAIN trial for Recurring GBM soon after
Alpha Tau (NASDAQ: $DRTS) Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange
Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings, Effective November 5, 2026
“Above all I want to mention our patients and their families, they are the real reason we get up in the morning. The true success of $DRTS won’t be measured solely by the market cap or share price, it will be measured first and foremost by the amount of people we help, the life we manage to extend and the hope we bring the families”
Alpha Tau CEO Uzi Sofer with a message at the TASE opening ceremony honoring his company